Discovery of effective systemic therapies for patients with advanced penile cancer has been slow to occur. Comprehensive genomic profiling from several studies shed light on the molecular oncogenesis of penile squamous cell carcinoma (PSCC) and differences between HPV-related and unrelated tumors. While these two subsets of PSCC appear distinct in their biology, there are not yet specific treatment strategies recommended on that basis. Cell surface proteins have been identified that may potentially serve as drug targets for monoclonal antibodies or small molecule inhibitors. Here, we review some of the new biological insights regarding PSCC that could lead to improved therapies, as well as the related clinical trials recently completed or in progress. We conclude that antibody-drug conjugates are especially promising, as are the combinations of immune checkpoint inhibitors with other types of drugs.
针对晚期阴茎癌患者有效全身疗法的发现进展缓慢。多项研究的综合基因组分析揭示了阴茎鳞状细胞癌（PSCC）的分子致癌机制，以及HPV相关与非相关肿瘤之间的差异。尽管这两类PSCC在生物学上存在明显区别，但目前尚未基于此差异形成特定的治疗策略。已发现一些细胞表面蛋白可能作为单克隆抗体或小分子抑制剂的药物靶点。本文综述了可能推动疗法改进的PSCC新生物学见解，以及近期已完成或正在进行的相关临床试验。我们认为抗体药物偶联物具有显著前景，免疫检查点抑制剂与其他类型药物的联合疗法同样值得期待。
Therapeutic Targets in Advanced Penile Cancer: From Bench to Bedside
肿瘤(癌症)患者之家